Want to see HK:0767 full AI Analyst Report?
Zhong Ji Longevity Science Group Limited (0767) AI Stock Analysis
Zhong Ji Longevity Science Group Limited
(HKEX:0767)
The overall score is constrained mainly by weak profitability and deteriorating cash flows, partially offset by a solid, low-leverage balance sheet and a moderately constructive technical trend, while negative earnings and no dividend keep valuation support limited.
Zhong Ji Longevity Science Group Limited (0767) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 299.23M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.84M
- Price to Earnings (P/E)
- -31.0
- Beta (1Y)
- 0.34
- Revenue Growth
- 9.93%
- EPS Growth
- 80.14%
- Country
- Hong Kong
- Employees
- 43
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Financial - Credit Services
Zhong Ji Longevity Science Group Limited Business Overview & Revenue Model
Company Description
Zhong Ji Longevity Science Group Limited operates as an investment holding entity, engaging in a broad spectrum of commercial endeavors. Its operations include providing money lending solutions across Hong Kong and Mainland China. The company's healt...
Zhong Ji Longevity Science Group Limited Financial Statement Overview
Summary
Profitability and cash generation are weak despite a solid balance sheet with low leverage; revenue growth has reversed and margins collapsed, leading to net losses and volatile operating cash flows.
Income Statement
35NegativeBalance Sheet
75PositiveCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 190.19M | 165.18M | 168.63M | 64.99M | 89.44M | 62.98M |
| Gross Profit | 22.06M | 16.74M | 57.41M | 56.28M | 79.41M | 49.40M |
| EBITDA | -1.96M | -7.37M | -23.10M | 13.02M | 15.99M | 16.13M |
| Net Income | -10.69M | -16.75M | -34.73M | 2.31M | -904.00K | 6.05M |
Balance Sheet | ||||||
| Total Assets | 551.08M | 499.91M | 525.63M | 509.25M | 484.84M | 517.50M |
| Cash, Cash Equivalents and Short-Term Investments | 13.40M | 24.30M | 47.84M | 81.08M | 60.07M | 19.44M |
| Total Debt | 5.62M | 5.57M | 19.11M | 20.20M | 11.76M | 12.93M |
| Total Liabilities | 113.62M | 74.92M | 125.49M | 78.79M | 63.99M | 46.78M |
| Stockholders Equity | 409.23M | 397.56M | 373.42M | 403.40M | 393.83M | 443.75M |
Cash Flow | ||||||
| Free Cash Flow | 10.75M | -23.13M | -61.76M | 15.28M | 11.08M | -40.51M |
| Operating Cash Flow | 10.75M | -23.12M | -61.05M | 15.28M | 12.11M | -39.62M |
| Investing Cash Flow | -27.26M | -23.03M | 11.47M | 382.00K | 16.59M | 2.91M |
| Financing Cash Flow | 2.20M | 24.70M | 15.17M | 6.02M | -7.45M | 3.44M |
Zhong Ji Longevity Science Group Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0767, the sentiment is Neutral. The current price of 0.48 is below the 20-day moving average (MA) of 0.48, below the 50-day MA of 0.48, and above the 200-day MA of 0.46, indicating a neutral trend. The MACD of 0.00 indicates Positive momentum. The RSI at 51.04 is Neutral, neither overbought nor oversold. The STOCH value of 32.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0767.
Zhong Ji Longevity Science Group Limited Peers Comparison
Overall Rating
HK:801962Neutral
HK:852554Neutral- HK:076751.3Neutral
HK:073645.5Neutral
HK:822338Underperform
HK:166033Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:8019 | 62Neutral | HKD 22.79M | 0.85 | 8.19% | ― | 4.25% | 182.18% |
| HK:8525 | 54Neutral | HKD 216.00M | 6.06 | 10.37% | ― | 74.12% | ― |
| HK:0767 | 51Neutral | HKD 302.41M | -30.97 | -2.65% | ― | 9.93% | 80.14% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:0736 | 46Neutral | HKD 84.53M | -0.76 | -17.33% | ― | 18.55% | -5.24% |
| HK:8223 | 38Underperform | HKD 170.28M | -5.52 | -2.60% | ― | -27.42% | 78.84% |
| HK:1660 | 33Underperform | HKD 1.15B | -115.00 | -3.17% | ― | -13.23% | 87.30% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0767 | Zhong Ji Longevity Science Group Limited | 0.48 | -0.05 | -9.43% | |
| HK:1660 | Zhaobangji Properties Holdings Limited | 0.18 | -0.33 | -63.92% | |
| HK:0736 | China Properties Investment Holdings Limited | 0.20 | -0.52 | -72.50% | |
| HK:8019 | Hao Wen Holdings Ltd. | 0.06 | -0.21 | -76.30% | |
| HK:8223 | Ziyuanyuan Holdings Group Ltd. | 0.26 | -0.54 | -67.50% | |
| HK:8525 | Baiying Holdings Group Ltd. | 0.80 | -0.05 | -5.88% |
Zhong Ji Longevity Science Group Limited Corporate Events
Zhong Ji Longevity Science Group Delays Circular on Cell Lab Stake Acquisition
Zhong Ji Longevity Science Group Limited has announced a further delay in sending a shareholder circular related to its proposed major and connected transaction to acquire 25% of Asian Integrated Cell Laboratory Limited via the issuance of convertibl...
Zhong Ji Longevity Science Tightens Terms on Cell Lab Stake Acquisition
Zhong Ji Longevity Science Group Limited has updated the terms of its major and connected transaction to acquire 25% of Asian Integrated Cell Laboratory Limited, a deal to be settled through the issue of convertible notes under a specific mandate. Fo...
Zhong Ji Longevity Science Schedules Board Meeting to Approve Interim Results and Potential Dividend
Zhong Ji Longevity Science Group Limited has scheduled a board meeting for 27 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also consider the potential declaration of an interim dividend a...
Zhong Ji Longevity Science Group to Launch RMB1 Billion Health-Focused M&A Fund
Zhong Ji Longevity Science Group’s Shenzhen-based subsidiary Zhong Ji Health has signed a memorandum of cooperation with Shenzhen Zhongtou Huijin Fund Management to jointly set up a specialized mergers and acquisitions fund targeting the big he...
Zhong Ji Longevity Science Group Clarifies Investment Strategy and Oversight in 2025 Report
Zhong Ji Longevity Science Group Limited has issued a supplemental announcement to its 2025 annual report detailing its cash and working capital management strategy and governance for significant investments. The company has established a Risk Manage...
Zhong Ji Longevity Science Group Wins Full Shareholder Backing at AGM
Zhong Ji Longevity Science Group Limited, a Bermuda-incorporated company listed in Hong Kong under stock code 767, operates in the longevity science sector and is subject to Hong Kong’s listing and corporate governance rules. Its board structur...
Zhong Ji Longevity Science Delays Circular on Asian Cell Lab Acquisition
Zhong Ji Longevity Science Group Limited is a Bermuda-incorporated company listed in Hong Kong that focuses on longevity-related science and healthcare businesses. The group is pursuing strategic investments in advanced biomedical operations, includi...
Zhong Ji Longevity Science Group Sets 2026 AGM to Approve Accounts, Board and Share Mandate
Zhong Ji Longevity Science Group Limited has called its annual general meeting for 30 June 2026 in Hong Kong, where shareholders will review the audited consolidated financial statements and directors’ and auditors’ reports for the year e...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 26, 2026